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Abstract
Kohonen self-organizing maps (SOMs) are unsupervised Artificial Neural Net-
works (ANNs) that are good for low-density data visualization. They easily deal
with complex and nonlinear relationships between variables. We evaluated molec-
ular events that characterize high- and low-grade BC pathways in the tumors from
104 patients. We compared the ability of statistical clustering with a SOM to strat-
ify tumors according to the risk of progression to more advanced disease. In uni-
variable analysis, tumor stage (log rank P = 0.006) and grade (P < 0.001), HPV
DNA (P < 0.004), Chromosome 9 loss (P = 0.04) and the A148T polymorphism
(rs 3731249) in CDKN2A (P = 0.02) were associated with progression. Multivari-
able analysis of these parameters identified that tumor grade (Cox regression,
P = 0.001, OR.2.9 (95% CI 1.6–5.2)) and the presence of HPV DNA (P = 0.017,
OR 3.8 (95% CI 1.3–11.4)) were the only independent predictors of progression.
Unsupervised hierarchical clustering grouped the tumors into discreet branches
but did not stratify according to progression free survival (log rank P = 0.39).
These genetic variables were presented to SOM input neurons. SOMs are suitable
for complex data integration, allow easy visualization of outcomes, and may strat-
ify BC progression more robustly than hierarchical clustering.
Introduction
Bladder cancer (BC) is a common disease for which the
outcomes have not improved in the last three decades
[1]. This probably reflects a lack of community-based
screening for the disease, that advanced BC responds
poorly to chemotherapy and that it can be hard to judge
the need for radical treatment in patients with non-mus-
cle invasive (NMI) disease. The latter arises primarily
from a lack of knowledge regarding the biology of this
disease. Clinicopathological and molecular data suggest
two distinct pathways of urothelial carcinogenesis [2, 3].
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Low-grade NMI cancers arise through regional deletion of
chromosome 9, mutation of FGFR3 (Fibroblast growth
factor receptor), and H-RAS [4]. High-grade tumors may
present with or before the onset of muscle invasion and
are best characterized by loss of (Tumor Protein) function
through direct (e.g., mutation or deletion of TP53) or
indirect (e.g., loss of RB1—Retinoblastoma or upregula-
tion of MDM2—Murine Double Minute) means [5].
High-grade tumors also have widespread chromosomal
instability (polysomy, aneuploidy) and numerous changes
to their epigenome [6,7].
While the two-pathway biology of BC is generally
accepted, many tumors have aspects of low- and high-grade
biology. For example, FGFR3 mutations are not found in
CIS (carcinoma in situ) but they coexist with TP53 muta-
tions in 10–20% of invasive BCs as do deletions of both
chromosome 9 (typical of low-grade disease) and 17p
(locus of TP53) in 15–74% BC [4, 8]. Clinical phenotypes,
therefore, reflect either the timing or impact of genetic
events combined with patient factors (such as type and
continued exposure to carcinogens) and treatment effec-
tiveness (such as timing, appropriateness and quality of
treatment). A current challenge for translational researchers
is to integrate distinct and, potentially, competing molecu-
lar events into single- phenotype predictions. In BC, this
represents the ability to discriminate future tumor behavior
using molecular alterations typical for low- and high-grade
tumor development. Nonstatistical methods are appealing
in this role as they do not rely upon data distribution, can
handle large datasets automatically without supervision or
prior assumptions, and do not assume that statistical prox-
imity equates to molecular association [9]. Various struc-
tures of artificial intelligence have been developed, of which
Artificial Neural Networks (ANNs) are perhaps the best
evaluated (reviewed in Ref. [10]). Here, we report the use
of a self-organizing map (SOM) to integrate molecular
parameters in BC. SOMs are a type of unsupervised ANNs
that are good for low-density data visualisation [11]. We
selected molecular events that characterize high- and low-
grade BC pathways and used progression to more advanced
disease as our primary outcome.
Materials and Methods
Patients, tumors, and samples
A total of 104 patients with BC were studied in this
report (data in Table 1). The tumors were chosen at ran-
dom to represent the disease spectrum from three Depart-
ments of Urology located in Lodz Macroregion, where
the textile industry was very popular in the previous
century. Tumors were graded according to 1973 WHO
classification and staged using the TNM criteria [12]. This
study was approved by the ethics committee of the Medi-
cal University of Lodz (No: RNN/99/11/KE) and all
patients gave written informed consent before entry.
RNA and DNA extraction
RNA and DNA were extracted from bladder tumors,
peripheral blood, and urinary sediments. For tumors,
frozen tissues were homogenized in TRI REAGENT
(guanidine thicyante/phenol, Molecular Research Center,
Inc. cat. No TR-118) using ceramic beads (Roche MagNA
Table 1. Genetic tests results, recurrence, and progression rate.
Overall n (%)
Kaplan–Meier analysis
Recurrence Progression
Rate
Log–rank
value Rate
Log–rank
value
Total 104 (100)
CHEK2 mutation
Yes 7 (6.7) 2 P = 0.858 2 P = 0.250
No 97 (93.3) 22 13
FGFR3 mutation
Yes 39 (37.5) 10 P = 0.618 5 P = 0.772
No 65 (62.5) 14 10
TP53 mutation
Yes 15 (14.4) 5 P = 0.291 11 P = 0.160
No 89 (85.6) 19 4
TP53 expression
Altered 29 (27.9) 2 P = 0.858 4 P = 0.924
Normal 75 (72.1) 22 11
Chromosome 9
LOH 33 (31.7) 5 P = 0.229 5 P = 0.743
No 71 (68.3) 19 10
Chromosome 13
LOH 6 (5.8) 0 P = 0.740 1 P = 0.740
No 98 (94.2) 24 14
Chromosome 17
LOH 12 (11.5 4 P = 0.405 2 P = 0.978
No 92 (88.5) 20 13
UroVysion test
Positive 74 (71.2) 16 P = 0.414 11 P = 0.930
Negative 30 (28.8) 8 4
CDKN2A polymorphism
148G/A 7 (6.7) 0 P = 0.298 2 P = 0.298
148G/G 97 (93.3) 24 13
CYP1B1 polymorphism
355T/T 14 (13.5) 4 P = 0.973 5 P = 0.417
355G/T 46 (42.2) 10 9
355G/G 44 (55.7) 10 10
TP53 polymorphism
72G/G 55 (52.9) 10 P = 0.106 10 P = 0.360
72G/C 41 (39.4) 10 5
72C/C 8 (7.7) 4 0
HPV DNA detected
Yes 14 (13.5) 3 P = 0.975 1 P = 0.02
No 90 (86.5) 21 13
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Lyser Green Beads, Roche Applied Science, Mannheim,
Germany, cat. No 3358941001) and the Roche Magna Lyser
(cat. No 03 358 976 001: three times for 45 sec at 9283 g).
Homogenized samples were cooled and RNA isolated by
acid guanidinum thiocyanate- phenol-chloroform extrac-
tion (according to the manufacturer’s protocol) [13]. Total
RNA was eluted in nuclease-free water and stored at
70°C. RNA was assessed for degradation, purity, and
DNA contamination by spectrophotometry and electro-
phoresis in 1.0% ethidium bromide-stained agarose gel.
Total RNA was DNase treated using DNase I (RNase free)
reagent (Ambion, Life Technologies Polska Sp. z o.o., War-
saw, Poland, cat. No AM2222). First-strand cDNAs were
synthesized from equal amounts of total RNA (0.5 lg/reac-
tion) using oligo(dT) and iScript cDNA Synthesis Kit (Bio-
Rad Polska Sp. z o.o., Warsaw, Poland, cat. No 70-8890)
according to the manufacturer’s instruction. For blood
samples, Roche MagNA Pure Compact automatic worksta-
tion was used to isolate DNA (Nucleic Acid Isolation Kit I-
Large Volume, cat. No 03 730 972 001, Roche Diagnostics
GmbH, Mannheim, Germany). For exfoliated urinary cells,
200–400 mL of freshly voided urine was collected in Carbo-
wax at diagnosis. DNA was isolated from urine sediment
with a Sherlock AX Kit according to manufacturer’s guide-
lines (A&A Biotechnology s.c., Gdynia, Poland).
Quantitative polymerase chain reaction
TP53 expression was measured using quantitative poly-
merase chain reaction (qPCR) performed using an iCycler
iQ System (Bio-Rad cat. No 170-8701, 1709750) [14].
Expression was determined SYBR Green I fluorescence
and normalized with respect to GAPDH (Glyceraldehyde-
3-Phosphate Dehydrogenase) and HPRT (Hypoxanthine–
guanine Phosphoribosyltransferase) genes.
Mutation and deletion detection
Mutations in TP53 (exons 4–8), CDKN2A (Cyclin-Depen-
dent Kinase inhibitor 2A, exons 1a, 2, and 3), and FGFR3
(exons 7, 10, 15) were detected using single strand confor-
mational polymorphism (SSCP) analysis and Sanger
sequencing, as detailed [15–17]. The mutations in CHEK2
(Chekpoint Kinase, IVS2 + 1G>A, 1100delC, and I157T)
gene were detected using multiplex PCR [18]. Loss of
heterozygosity (LOH) for the TP53,/ARF, and RB1 genes
was studied using PCR technique with malignant and wild-
type (blood, genomic) DNA [19].
UroVysion test
The UroVysion (Vysis) test consists of a four-color, four-
probe mixture of DNA probe sequences homologous to
specific regions on chromosomes 3, 7, 9, and 17, and was
carried out according to the manufacturer’s protocol.
Human papilloma virus detection
Human Papilloma Virus (HPV) DNA was detected using
the LINEAR ARRAY Human Papillomavirus GENOTYP-
ING Test in cancer tissue (Roche, includes 37 pathogenic
genotypes: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70,
71, 72, 73, 81, 82, 83, and 84) according to manufac-
turer’s protocol.
Generation of a self-organizing map
The dataset (10 genetic variables 9 104 patients) was pre-
sented to 10 input neurons seven times in the rough-train-
ing phase and 27 times in the fine-tuning phase. The
number of the input neurons was equal to the number of
variables in the dataset. On a basis of the established link
between the input and output neurons, a virtual patient
(in terms of values of the genetic variables presented to
the SOM) was created in each output neuron. The output
neurons were arranged on a two-dimensional grid
(4 9 4). To cluster the virtual patients (and respective
output neurons), the hierarchical cluster analysis with the
Ward linkage method and Euclidean distance measure was
used [20–22]. Finally, each real patient was assigned to the
best matching virtual patient and the respective output
neuron. The SOM training process was performed with
the use of the SOM Toolbox developed by the Laboratory
of Information and Computer Science in the Helsinki
University of Technology (http://www.cis.hut.fi/projects/
somtoolbox/) in Matlab environments [23, 24]. The signif-
icance of differences between subclusters was assessed: 1)
with the Tichy and Chytry analysis and the Monte Carlo
randomization test carried out with PC-ORD software for
binary variables, and 2) with the Kruskal–Wallis test and
the post hoc Dunn test for the variables measured at the
ordinal or ratio level (STATISTICA Vsn. 10, 2011, StatSoft
Polska Sp. z o.o., Krakow, Poland) [25].
Statistical data analysis
The primary aim of our study was to evaluate the ability
of the SOM at integrating molecular data from BC
samples. To this end, we analyzed its ability to stratify
tumor progression using log-rank analysis and by plotting
survival using the Kaplan–Meier method (SPSS Vsn. 19.0,
IBM Inc., New York, NY) (Fig. 1). Progression was
defined as pathological or radiological evidence or wors-
ening tumor stage. The most common examples were the
development of muscle invasion from a NMI tumor, and
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or metastases from an invasive cancer. Both these events
mark a significant deterioration in prognosis for the
patient and a need to alter treatment intent. For compari-
son with the SOM, we used an unsupervised hierarchical
approach to cluster tumors using city block distance and
average linkage in Cluster 3.0 (Eisen Lab, University of
California, Berkeley, CA) and Tree view.
Results
Patients and tumors
The population studied was typical for bladder cancer.
Most patients were male; the average age was 66 years
(66  11), and most had a history of cigarette smoking.
Around 2/3 of tumors were NMI (Table 1) and most
were of low or moderate grade. Following treatment,
recurrence was observed in 24 patients (23%) and pro-
gression to invasion or metastases in 15 (14%).
Genetic analysis of tumors
Genetic analysis revealed various molecular abnormalities
(Table 1 and Fig. 2). For example, mutations were found
in FGFR3 (n = 39, 38%), TP53 (n = 15, 14%), and CHEK2
(n = 7, 7%) tumors. Overall mutations were detected in 50
(48%) tumors, including 11 with more than one (six with
FGFR3 and TP53, and five with FGFR3 and CHEK2 muta-
tions). Chromosomal loss was found in 41 (39%) tumors,
including nine with more than one chromosome affected.
While mutations of CHEK2 (n = 7, 7%) and deletions of
chromosome 13 (n = 6, 6%) were uncommon, the UroVy-
sion test was positive in 74 (72%) samples.
Progression from genetic markers
The primary outcome for our study was disease progres-
sion to a more advanced stage. In univariable analysis,
tumor stage (log rank P = 0.006) and grade (P < 0.001),
Figure 1. Hierarchical clustering of samples.
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HPV DNA (P < 0.004), Chromosome 9 (P = 0.04) and
the A148T polymorphism (rs 3731249) in CDKN2A
(P = 0.02) were associated with progression following
treatment. Multivariable analysis of these parameters
identified that tumor grade (Cox regression, P = 0.001,
OR 2.9 (95% CI 1.6–5.2)) and the presence of HPV DNA
(P = 0.017, OR 3.8 (95% CI 1.3–11.4) were the only
independent predictors of progression. Unsupervised hier-
archical clustering grouped the tumors into several
branches (Figs. 1 and 3). This approach did not signifi-
cantly stratify progression free survival (log rank
P = 0.39).
Clusters
The two main clusters of SOM output neurons were dis-
tinguished: X and Y, each with a pair of sub-clusters: X1
and X2, and Y1 and Y2 (Fig. 4). Patients with the worst
prognosis were assigned to X1 and X2 (UroVysion test
positive in 100% and 93%, respectively, and high fre-
quency of TP53 mutations, data in Table 2 and Fig. 2).
The highest frequency of: (1) abnormal TP53 expression
(57%) and (2) heterozygocity loss for 9, 13 and 17 chro-
mosome loci (71%) was recorded for patients in subclus-
ter X2. In Y1 the UroVysion test was negative for all
patients, and the FGFR3 mutation ratio was quite high
(38%). In Y2 the UroVysion test was positive in 86%
patients and all of them had FGFR3 gene mutation. These
differences were also reflected in clinical variables
(Table 2). Tumors with high grade and higher diameter
were grouped mostly in subcluster X1 and X2. The highest
ratio of recurrences (29%) was observed in subcluster Y1,
where were only negative results of UroVysion test and
none TP53 mutations. Significant difference in frequency
Figure 2. Pathological and molecular features of the individual tumors in this report. No patients were assigned to the nonlisted SOM neurons
(B1, B3, C2-C4 and D2; see Fig. 4).
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of patients with polymorphism A148T of CDKN2A gene,
LOH frequency and TP53 altered expression were
observed between subclusters. Some other interesting
observation can be noticed like negative correlation
between CDKN2A and TP53 gene polymorphism Figure 5
is showing SOM component planes used to form the
rules and their values with scale (down right-hand side of
each histogram); components describe various characteris-
tics of the subclusters.
Discussion
Our knowledge of the molecular changes in BC has con-
siderably grown over recent years [25]. Currently, a num-
ber of conventional clinicopathological factors are useful
in predicting survival of bladder cancer patients. These
include tumor grade, stage, type, size, the presence of
concomitant carcinoma in situ, patient age, tumor loca-
tion, and presence of multiple tumors [26]. As yet,
there are no criteria that robustly predict the clinical out-
come for individual patients with BC. Improvements in
prediction may be made by the gain of information (e.g.,
through molecular biology) or by alternate methods of
analysis. With this in mind, we have undertaken this
study to evaluate the ability of SOM to integrate clinical–
molecular information for stratifying outcomes in BC.
Traditionally, statistical techniques such as Cox’s propor-
tional hazards and logistic regression are usually
employed when analyzing prognostic information. Classic
statistical modeling requires the explicit assumption of
certain relationships within the data that are often unpro-
ven. ANNs offer a number of theoretical advantages,
including ability to detect complex nonlinear relationships
between variables, ability to detect all possible interactions
between predictor variables, and the availability of multi-
ple training algorithms [27]. The ANN techniques
depicted in the literature can be mainly categorized under
two headings: supervised and unsupervised. Kohonen
SOM consists in a feed forward neural network that uses
an unsupervised training (partitional clustering). It means
that, the data are directly divided into a set of clusters
without any regard to the relationships between the clus-
ters. These methods try to maximize some measure of
similarity within the units (patients) of each cluster,
Figure 3. Recurrence and progression following treatment stratified using a self-organizing map.
Figure 4. The output layer of the self organizing map applied. Clusters X, Y, and subclusters (X1, X2, Y1, and Y2) of virtual patients and
respective output neurons have been identified on the basis of the hierarchical cluster analysis.
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Table 2. Results of the Kohonen SOM classifier (ns, not significant, *Kruskal–Wallis, **Tichy and Chytry).
Variables
Subcluster Subcluster Subcluster Subcluster
P value
X1 X2 Y1 Y2
n (%) n (%) n (%) n (%)
Total No of patients 24 (23.0) 28 (27.0) 24 (23.0) 28 (27.0)
Mean age 64 75.5 70.5 69
No female 2 4 5 1
Grade
G1 10 (41.7) 13 (46.4) 19 (79.2) 18 (64.3) <0.001*
G2-3 14 (58.3) 15 (53.6) 5 (12.5) 10 (21.4)
Stage
Ta 16 (66.7) 15 (53.6) 19 (79.2) 20 (71.4) ns*
T1 3 (12.5) 8 (28.6) 5 (20.8) 5 (17.9)
T2–T4 5 (20.8) 5 (17.8) 0 3 (10.7)
Smoking history
Current and ex 24 (100) 26 (92.9) 22 (91.7) 27 (96.4) ns**
Never 0 2 (7.1) 2(8.3) 1 (3.6)
Occupational exp.
Yes 9 (37.5) 9 (32.1) 9 (37.5) 12 (42.9) ns**
No 15 (62.5) 19 (67.9) 15 (62.5) 16 (57.1)
No of tumors
1 18 (75.0) 18 (64.3) 17 (63.0) 21 (75.0) ns*
>1 6 (25.0) 10 (35.7) 7 (37.0) 7 (25.0)
Tumor diameter
2 cm 10 (41.7) 7 (25.0) 19 (79.2) 18 (64.3) <0.001*
>2 cm 14 (58.3) 21 (75.0) 5 (20.8) 10 (35.7)
Local recurrence
Yes 5 (21.0) 7 (25.0) 7 (29.2) 5 (17.9) ns**
No 19 (79.0) 21 (75.0) 17 (70.8) 23 (82.1)
HPV infection
Yes 4 (16.6) 4 (14.3) 3 (12.5) 3 (10.7) ns**
No 20 (83.4) 24 (85.7) 21 (87.5) 25 (89.3)
CHEK2 mutation
Yes 2 (8.3) 1 (3.6) 1 (4.2) 3 (10.7) ns**
No 22 (91.7) 27 (96.4) 23 (95.8) 25 (89.3)
FGFR3 mutation
Yes 1 (4.2) 1 (3.6) 9 (37.5) 28 (100) <0.001**
No 23 (95.8) 27 (96.4) 15 (62.5) 0
TP53 mutation
Yes 5 (20.8) 5 (17.9) 0 5 (17.9) ns**
No 19 (79.2) 23 (82.1) 24 (100) 23 (82.10
TP53 expression
Altered 1 (4.2) 16 (57.1) 1 (4.2) 11 (39.3) <0.01**
Normal 23 (95.8) 12 (42.9) 23 (95.8) 17 (60.7)
LOH chromosome 9
Yes 1 (4.2) 17 (60.7) 7 (37.0) 8 (28.6) <0.001**
No 23 (95.8) 11 (39.3) 17 (63.0) 20 (71.4)
LOH chromosome 13
Yes 1 (4.2) 3 (10.7) 2 (8.3) 0 ns**
No 23 (95.8) 25 (89.3) 22 (91.7) 28 (100)
LOH chromosome 17
Yes 2 (8.3) 8 (28.6) 0 2 (7.1) <0.01**
No 22 (91.7) 20 (71.4) 24 (100) 26 (92.9)
UroVysion test
Positive 24 (100) 26 (92.9) 0 24 (85.7) <0.001**
Negative 0 2 (7.1) 24 (100) 4 (14.3)
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while minimizing the similarity between clusters [28].
SOM is combination of partitional clustering and projec-
tion methods. It can be used at the same time both to
reduce the amount of data by clustering and to construct
nonlinear projection of the data onto a low-dimensional
display. In contrast to other clustering methods, the
units in SOM become organized in such a way that
nearby units on the gird are similar to another. The
Figure 5. The associations (stronger if brighter red) of virtual patients’ features with SOM regions. The intensity of colours is scaled
independently for each variable. Variables with the same pattern over SOM are positively correlated. If the frequency of real patients with a given
feature is significantly highest in any subcluster as compared to others, the symbol of the subcluster and the respective significance level
(*P < 0.05; **P < 0.01; ***P < 0.001) are shown along with the variable name.
Table 2. Continued.
Variables
Subcluster Subcluster Subcluster Subcluster
P value
X1 X2 Y1 Y2
n (%) n (%) n (%) n (%)
CDKN2A polymorphism
Ala/Thr 5 (20.8) 1 (3.6) 1 (4.2) 0 <0.05**
Ala/Ala 19 (79.2) 27 (96.4) 23 (95.8) 28 (100)
CYP1B1 polymorphism
355T/T 5 (20.8) 3 (10.7) 1 (4.2) 5 (17.9) ns**
355T/T and T/G 19 (79.2) 25 (89.3) 23 (95.8) 23 (82.1)
TP53 polymorphism
Arg 16 (66.6) 15 (53.6) 13 (54.2) 11 (39.3) ns**
Arg/Pro 7 (29.2) 12 (42.9) 9 (37.5) 13 (46.4)
Pro 1 (4.2) 1 (3.5) 2 (8.3) 4 (14.3)
1232 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Kohonen Maps in Bladder Cancer E. M. Borkowska et al.
topology of the gird can be anything but in practice
rectangular two-dimensional girds are preferred as they
are easy to display [28, 29].
In managing patients with BC, one of the principal
problems for the clinician is prediction tumor recurrence
and progression. It is likely that a combination of clini-
cal, pathological, and molecular data are needed to opti-
mize these outcome predictions. The future of molecular
biomarkers in BC undoubtedly lies in of panels of mark-
ers that represent high- and low-grade disease. Examples
of these include FGFR3 and TP53 mutations that are
associated with a better or worse prognosis, respectively
[30]. Additional genetic changes that reflect underlying
malignant traits, such as numerical chromosomal alterna-
tions from genetic instability, are useful as they identify
global patterns within a disease rather than focusing
upon specific events [31]. In this work, we included
many of these changes in an attempt to genotype
tumors. In 2010, Catto et al. and Kim et al. identified
six and eight progression-related genes in BC from
microarray and either neurofuzzy modeling or hierarchi-
cal clustering, respectively [32, 33]. Of interest, the genes
in these panels do not overlap, as found in other cancers
[34, 35]. Here, we used SOM to explore a similar clinical
scenario. We found that the SOM was easily understood
by the clinician and could cluster tumors according to
future clinical outcomes. SOMs appear to do this better
than more traditional statistical analyses. In clinical care,
this stratification could identify aggressive tumors need-
ing early radical treatment and indolent ones suitable for
less intense surveillance. The potential for SOMs is in
real time help to guide patient choices. For example, in
breast cancer detection, an unsupervised ANN model
improved diagnosing performance when compared to
classical feed-forward neural networks like multilayer
perceptron (MLP), radial basis function (RBF), and
probabilistic neural networks (PNN) [36, 37]. Thus, it is
possible that SOMs could be integrated into patient
pathways and used to guide their surveillance frequency
or even treatment intent. There are a number of limita-
tions to our work. For example, the analysis was based
on a relatively low number of patients with a low event
rate (number of cases with progression). However, we
analysed a large number of genetic events that are
known to characterize distinct BC molecular pathways,
and as such, this work represents the first in BC to inte-
grate clinical, molecular, and environmental prognostic
biomarkers.
Conclusions
We have shown that Kohonen SOM could cluster homoge-
nous tumors according to genotype and that this stratified
clinical outcomes when analyzed. SOMs are easy to
understand and potentially outperform traditional statis-
tical analyses. As such, their use needs more evaluation
but they could potentially offer a real-time solution to
integrating molecular data into patient pathways.
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